Takeda and Amylin Pharmaceuticals have selected a combination of pramlintide and metreleptin for Phase III development for obesity following disappointing results with davalintide, another candidate being investigated under the two firms' global alliance for the indication.
The decision follows positive results from a Phase II extension study with the combination, which showed benefits over placebo in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?